Myriad Genetics Inc. Reaches New 12-Month Low at $22.61 (MYGN)
Myriad Genetics (NASDAQ:MYGN)’s share price reached a new 52-week low during trading on Monday, Analyst Ratings Network.com reports. The stock traded as low as $22.61 and last traded at $23.50, with a volume of 3,900,238 shares traded. The stock had previously closed at $25.92.
A number of analysts have recently weighed in on MYGN shares. Analysts at Ned Davis Research downgraded shares of Myriad Genetics (NASDAQ:MYGN) from a “buy” rating to a “neutral” rating in a research note to investors on Monday. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Myriad Genetics (NASDAQ:MYGN) in a research note to investors on Thursday, September 19th. They now have a $27.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Myriad Genetics (NASDAQ:MYGN) in a research note to investors on Friday, August 16th. They now have a $29.00 price target on the stock. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $34.23.
Myriad Genetics has a 52-week low of $22.61 and a 52-week high of $38.27. The stock’s 50-day moving average is $26.86 and its 200-day moving average is $28.45. The company has a market cap of $1.890 billion and a P/E ratio of 14.64.
Myriad Genetics (NASDAQ:MYGN) last released its earnings data on Tuesday, August 13th. The company reported $0.53 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.44 by $0.09. The company had revenue of $174.10 million for the quarter, compared to the consensus estimate of $159.87 million. During the same quarter in the prior year, the company posted $0.34 earnings per share. The company’s quarterly revenue was up 30.9% on a year-over-year basis. Analysts expect that Myriad Genetics will post $1.91 EPS for the current fiscal year.
Myriad Genetics, Inc (NASDAQ:MYGN) is a molecular diagnostic company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.